MétaCan
Menu
Back to cohort
Record W2944535240 · doi:10.1016/j.bbmt.2019.05.007

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation

2019· article· en· W2944535240 on OpenAlexaff
Ayman Saad, Lawrence S. Lamb, Tao Wang, Michael Hemmer, Stephen R. Spellman, Daniel R. Couriel, Amin M. Alousi, Joseph Pidala, Hisham Abdel‐Azim, Vaibhav Agrawal, Mahmoud Aljurf, Amer Beitinjaneh, Vijaya Raj Bhatt, David Buchbinder, Michael Byrne, Jean‐Yves Cahn, Mitchell S. Cairo, Paul Castillo, Saurabh Chhabra, Miguel Ángel Díaz, Shatha Farhan, Yngvar Fløisand, Hadar A. Frangoul, Shahinaz M. Gadalla, James Gajewski, Robert Peter Gale, Manish J. Gandhi, Usama Gergis, Betty K. Hamilton, Peiman Hematti, Gerhard Hildebrandt, Rammurti T. Kamble, Abraham S. Kanate, Pooja Khandelwal, Aleksandr Lazaryan, Margaret L. MacMillan, David I. Marks, Rodrigo Martino, Parinda A. Mehta, Taiga Nishihori, Richard F. Olsson, Sagar S. Patel, Muna Qayed, Hemalatha G. Rangarajan, Ran Reshef, Olle Ringdén, Bipin N. Savani, Harry C. Schouten, Kirk R. Schultz, Sachiko Seo, Brian C. Shaffer, Melhem Solh, Takanori Teshima, Álvaro Urbano-Ispizúa, Leo F. Verdonck, Ravi Vij, Edmund K. Waller, Basem M. William, Baldeep Wirk, Jean A. Yared, Lolie C. Yu, Mukta Arora, Shahrukh K. Hashmi

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2019
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsBC Children's HospitalUniversity of British Columbia
FundersNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchPharmacyclicsKite PharmaHealth Resources and Services AdministrationSwedish Orphan BiovitrumJanssen Scientific AffairsMundipharma EDOAstellas PharmaAdaptive Biotechnologiesbluebird bioChimerixMedical College of WisconsinTakeda OncologyUniversity of MinnesotaKaryopharm TherapeuticsU.S. NavyCelgeneU.S. Public Health ServiceU.S. Department of DefenseSanofiU.S. Department of Health and Human ServicesAstellas Pharma USHistoGeneticsSanofi GenzymePatient-Centered Outcomes Research InstituteBristol-Myers SquibbMedacJazz PharmaceuticalsBe The Match FoundationSpectrum PharmaceuticalsNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals CorporationIncytePfizerAmgenAtara BiotherapeuticsNational Cancer InstituteGilead Sciences
KeywordsMedicineCumulative incidenceTransplantationGastroenterologyInternal medicineStem cellCD3Univariate analysisImmunologyHematopoietic stem cell transplantationHuman leukocyte antigenOncologyCD8Immune systemMultivariate analysisAntigenBiology

Abstract

fetched live from OpenAlex

Data on whether the T cell dose of allogeneic peripheral blood stem cell (PBSC) products influences transplantation outcomes are conflicting. Using the Center for International Blood and Marrow Transplant Research database, we identified 2736 adult patients who underwent first allogeneic PBSC transplantation for acute leukemia or myelodysplastic syndrome between 2008 and 2014 using an HLA-matched sibling donor (MSD) or an 8/8-matched unrelated donor (MUD). We excluded ex vivo and in vivo T cell-depleted transplantations. Correlative analysis was performed between CD3 + T cell dose and the risk of graft-versus-host-disease (GVHD), relapse, nonrelapse mortality (NRM), disease-free survival (DFS), and overall survival (OS). Using maximum likelihood estimation, we identified CD3 + T cell dose cutoff that separated the risk of acute GVHD (aGVHD) grade II-IV in both the MSD and MUD groups. A CD3 + T cell dose cutoff of 14 × 10 7 cells/kg identified MSD/low CD3 + (n = 223) and MSD/high CD3 + (n = 1214), and a dose of 15 × 10 7 cells/kg identified MUD/low CD3 + (n = 197) and MUD/high CD3 + (n = 1102). On univariate analysis, the MSD/high CD3 + group had a higher cumulative incidence of day +100 aGVHD grade II-IV compared with the MSD/low CD3 + group (33% versus 25%; P = .009). There were no differences between the 2 groups in engraftment rate, risk of aGVHD grade III-IV or chronic GVHD (cGVHD), NRM, relapse, DFS, or OS. The MUD/high CD3 + group had a higher cumulative incidence of day +100 aGVHD grade II-IV compared with the MUD/low CD3 + group (49% versus 41%; P = .04). There were no differences between the 2 groups in engraftment rate, risk of severe aGVHD or cGVHD, NRM, relapse, DFS, or OS. Multivariate analysis of the MSD and MUD groups failed to show an association between CD3 + T cell dose and the risk of either aGVHD grade II-IV ( P = .10 and .07, respectively) or cGVHD (P = .80 and .30, respectively). Subanalysis of CD4 + T cells, CD8 + T cells, and CD4+/CD8+ ratio failed to identify cutoff values predictive of transplantation outcomes; however, using the log-rank test, the sample size was suboptimal for identifying a difference at this cutoff cell dose. In this registry study, the CD3 + T cell dose of PBSC products did not influence the risk of aGVHD or cGVHD or other transplantation outcomes when using an MSD or an 8/8-matched MUD. Subset analyses of CD4 + and CD8 + T cell doses were not possible given our small sample size.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.265
Teacher spread0.250 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2019
Admission routes1
Has abstractno

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207